The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
NCT06414356 · Margaux M. Salas, PhD
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Defense and Veterans Pain Rating Score (DVPRS)
Measured over Up to 32 weeks
Brief Pain Inventory Scale (BPI)
Measured over Up to 32 weeks
Life Satisfaction Questionnaire (LiSAT)
Measured over Up to 32 weeks
Post-traumatic Stress Disorder Checklist (PCL-5)
Measured over Up to 32 weeks
The Patient-Reported Outcomes Measurement Information System (PROMIS 29+2)
Measured over Up to 32 weeks
Patient Health Questionnaire-9 (PHQ-9)
Measured over Up to 32 weeks
Generalized Anxiety Disorder Scale
Measured over Up to 32 weeks
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Brooke Army Medical Center | San Antonio | Texas | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT06414356 on ClinicalTrials.gov →
Last updated in the registry 2025-02-25. Registry records change; this page reflects the data build of 2026-08-25.
Related